CL2014001637A1 - Preparacion que comprende emodepsido en forma amorfa en una matriz de polivinilpirrolidona; producto farmaceutico que la comprende; y su uso para controlar endoparasitos en seres humanos o animales tales como dirofilaria immitis. - Google Patents

Preparacion que comprende emodepsido en forma amorfa en una matriz de polivinilpirrolidona; producto farmaceutico que la comprende; y su uso para controlar endoparasitos en seres humanos o animales tales como dirofilaria immitis.

Info

Publication number
CL2014001637A1
CL2014001637A1 CL2014001637A CL2014001637A CL2014001637A1 CL 2014001637 A1 CL2014001637 A1 CL 2014001637A1 CL 2014001637 A CL2014001637 A CL 2014001637A CL 2014001637 A CL2014001637 A CL 2014001637A CL 2014001637 A1 CL2014001637 A1 CL 2014001637A1
Authority
CL
Chile
Prior art keywords
emodepside
humans
animals
preparation
pharmaceutical product
Prior art date
Application number
CL2014001637A
Other languages
English (en)
Inventor
Venkata Rangarao Kanikanti
Petra Lange
Hans Junger Hamann
Peter Kleinebudde
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2014001637A1 publication Critical patent/CL2014001637A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CL2014001637A 2011-12-21 2014-06-19 Preparacion que comprende emodepsido en forma amorfa en una matriz de polivinilpirrolidona; producto farmaceutico que la comprende; y su uso para controlar endoparasitos en seres humanos o animales tales como dirofilaria immitis. CL2014001637A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11194878 2011-12-21

Publications (1)

Publication Number Publication Date
CL2014001637A1 true CL2014001637A1 (es) 2014-11-21

Family

ID=47358491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001637A CL2014001637A1 (es) 2011-12-21 2014-06-19 Preparacion que comprende emodepsido en forma amorfa en una matriz de polivinilpirrolidona; producto farmaceutico que la comprende; y su uso para controlar endoparasitos en seres humanos o animales tales como dirofilaria immitis.

Country Status (24)

Country Link
US (3) US9539331B2 (es)
EP (1) EP2793861B1 (es)
JP (1) JP6185930B2 (es)
KR (2) KR101979049B1 (es)
CN (2) CN108187028A (es)
AU (2) AU2012357848C1 (es)
BR (1) BR112014014973A2 (es)
CA (1) CA2859787C (es)
CL (1) CL2014001637A1 (es)
CO (1) CO6990713A2 (es)
CR (1) CR20140293A (es)
DO (1) DOP2014000140A (es)
EC (1) ECSP14005917A (es)
ES (1) ES2734352T3 (es)
HK (1) HK1255536A1 (es)
IL (1) IL233183B (es)
MX (2) MX356094B (es)
MY (1) MY175307A (es)
NI (1) NI201400065A (es)
PH (2) PH12014501438B1 (es)
RU (2) RU2651761C2 (es)
UA (1) UA115232C2 (es)
WO (1) WO2013092558A1 (es)
ZA (1) ZA201404529B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175307A (en) 2011-12-21 2020-06-18 Bayer Ip Gmbh Preparations comprising amorphous emodepside
BR112017024773A2 (pt) 2015-05-20 2018-11-06 Merial, Inc. compostos depsipeptídeos anti-helmínticos
CA3009867C (en) 2015-12-28 2022-05-31 Merial, Inc. Anthelmintic cyclic depsipeptide compounds
WO2018093920A1 (en) 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
CN114195732A (zh) * 2022-01-04 2022-03-18 丽珠集团福州福兴医药有限公司 一种艾默德斯的单晶型iii及其制备方法
CN115444927B (zh) * 2022-09-19 2023-06-02 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 艾默德斯在制备治疗三阴性乳腺癌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2874342B2 (ja) 1992-03-17 1999-03-24 藤沢薬品工業株式会社 デプシペプチド誘導体,その製法およびその用途
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2315614C1 (ru) * 2006-04-19 2008-01-27 Бийтемир Ахмедович Султанбеков Средство "грепол" и способ применения его при паразитарных заболеваниях
PL2118055T3 (pl) * 2007-02-09 2014-01-31 Zoetis Uk Ltd Środki przeciwpasożytnicze
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
WO2010054833A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Intermediate und orale darreichungsformen enthaltend lenalidomid
DE102009012423A1 (de) 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
MY175307A (en) 2011-12-21 2020-06-18 Bayer Ip Gmbh Preparations comprising amorphous emodepside

Also Published As

Publication number Publication date
US20140371139A1 (en) 2014-12-18
UA115232C2 (uk) 2017-10-10
AU2018202376B2 (en) 2019-06-20
CN108187028A (zh) 2018-06-22
NZ625817A (en) 2016-08-26
ES2734352T3 (es) 2019-12-05
PH12014501438A1 (en) 2014-10-08
RU2018105003A (ru) 2019-02-22
IL233183B (en) 2020-01-30
US10251932B2 (en) 2019-04-09
AU2012357848B2 (en) 2018-01-04
MX356094B (es) 2018-05-14
AU2018202376A1 (en) 2018-04-26
MY175307A (en) 2020-06-18
CA2859787C (en) 2020-09-08
WO2013092558A1 (de) 2013-06-27
KR101978620B1 (ko) 2019-08-28
PH12018500368A1 (en) 2018-07-23
NI201400065A (es) 2015-12-10
RU2014129620A (ru) 2016-02-10
EP2793861A1 (de) 2014-10-29
AU2012357848A1 (en) 2014-07-10
JP6185930B2 (ja) 2017-08-23
KR101979049B1 (ko) 2019-05-15
MX368209B (es) 2019-09-24
ECSP14005917A (es) 2015-12-31
RU2761529C2 (ru) 2021-12-09
US20180153957A1 (en) 2018-06-07
JP2015502377A (ja) 2015-01-22
DOP2014000140A (es) 2014-07-31
CN104023710A (zh) 2014-09-03
AU2012357848C1 (en) 2018-07-19
BR112014014973A2 (pt) 2017-06-13
KR20180084141A (ko) 2018-07-24
PH12014501438B1 (en) 2014-10-08
RU2651761C2 (ru) 2018-04-23
US9539331B2 (en) 2017-01-10
CO6990713A2 (es) 2014-07-10
US20170182118A1 (en) 2017-06-29
ZA201404529B (en) 2017-06-28
KR20140107296A (ko) 2014-09-04
IL233183A0 (en) 2014-07-31
RU2018105003A3 (es) 2021-06-11
HK1255536A1 (zh) 2019-08-23
CR20140293A (es) 2014-07-14
CA2859787A1 (en) 2013-06-27
MX2014007224A (es) 2014-09-22
EP2793861B1 (de) 2019-05-01

Similar Documents

Publication Publication Date Title
CL2015000128A1 (es) Composición para controlar enfermedades en plantas y el uso de la misma
IL289759A (en) Formulations for local disinfection and their uses
CL2014001637A1 (es) Preparacion que comprende emodepsido en forma amorfa en una matriz de polivinilpirrolidona; producto farmaceutico que la comprende; y su uso para controlar endoparasitos en seres humanos o animales tales como dirofilaria immitis.
HRP20181364T8 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
CL2014003357A1 (es) Composición sinérgica para la protección de cultivos agrícolas y su uso
GB2540638B (en) Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
CL2014000467A1 (es) Formulación que comprende cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados; metodo para obtener sustancia efectiva como plaguicida derivada de la formulación antes indicada.
IL263978B (en) Amorphous latrovir and solid pharmaceutical preparations containing it and its uses
SG11201406141UA (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
ZA201400878B (en) Plant disease control composition and its use
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
ZA201401435B (en) Pesticidal compositions with enhanced active ingredient retention in pest control zones
EP2753179A4 (en) TOPICAL FORMULATIONS OF ITRACONAZOLE AND USES THEREOF
CL2015000714A1 (es) Composición para el control de plagas y uso de la misma
AP2014007616A0 (en) Agrochemical formulation and use thereof
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
BR302012005224S1 (pt) "configuração aplicada em jogo para transporte de material biológico
PL2394511T3 (pl) Synergistycznie działające mieszaniny enancjomerów alfa, omega-aminoalkoholu, ich wytwarzanie oraz ich zastosowanie w kompozycjach do odstraszania owadów i roztoczy